Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMycelx Di Regulatory News (MYX)

Share Price Information for Mycelx Di (MYX)

Share Price is delayed by 15 minutes
Get Live Data
64.00    2.00 (3.23%)
Bid:
63.00
Ask:
65.00
Spread: 2.00 (3.175%)
Market Cap: £15.59m
MYX Live PriceLast checked at - London Stock Exchange

Intraday Mycelx Di Share Chart

Director/PDMR Shareholding

21 May 2015 15:01

RNS Number : 9589N
MyCelx Technologies Corporation
21 May 2015
 



MyCelx Technologies Corporation

("MyCelx" or the "Company") (AIM: MYX)

 

21 May 2015

 

Grant of Share Option to Director

 

The Company announces that it has been notified on 20 May 2015 by Mark Clark, Chief Financial Officer and a director of the Company, that he was granted an option on 20 May 2015 under the MyCelx Omnibus Performance Incentive Plan ("Plan") over the Company's common shares of US$0.025 each ("Common Shares"). The grant to Mr. Clark was as follows:

 

Name of Director

Number of share options granted

Exercise price

Total number of share options held following this notification

Total number of share options as % of current issued share capital

Mark Clark

20,000

US$2.15 *

81,667

0.44%

 

In addition, following this transaction, Mr. Clark continues to be interested in 47,553 Common Shares, representing 0.26 per cent of the present issued capital of the Company.

 

Grant of Share Option to Chief Business Development Officer

 

The Company further announces that it has been notified on 20 May 2015 by Connie Mixon, Chief Executive Officer and a director of the Company, that her husband Mark Mixon, Chief Business Development Officer, was granted an option on 20 May 2015 under the Plan over 76,000 Common Shares. The grant to Mr. Mixon was as follows:

 

Name

Number of share options granted

Exercise price

Total number of share options held following this notification

Total number of share options as % of current issued share capital

Mark Mixon

76,000

US$2.15 *

200,204

1.07%

 

In addition, following this transaction, Mr. Mixon continues to be interested in 10,000 Common Shares, representing 0.05 per cent of the present issued capital of the Company, which he holds as custodian for his son.

 

Following this transaction, Ms. Mixon is interested in an aggregate (including the interests of Mr. Mixon) of 991,210 Common Shares, representing 5.32 per cent of the present issued capital of the Company, and in options over an aggregate (including the interests of Mr. Mixon) of 363,221 Common Shares, representing 1.95 per cent of the present issued capital of the Company.

 

The aggregate number of Common Shares held by Ms. Mixon also includes (a) 150,000 shares held by limited liability companies controlled by Ms. Mixon; and (b) 202,646 shares held by or on behalf of Ms. Mixon's children.

 

The above grants formed part of wider grants of 319,000 options to a total of fifteen employees across the Company, on the same date, representing 1.71% of the current issued share capital.

 

The share options granted on 20 May 2015 will vest as to one third on each of the first, second and third anniversaries of the date of grant, and must be exercised prior to the tenth anniversary of the date of grant, subject to the restrictions on dealing under the Company's share dealing code.

 

*Based on the mid-market closing price of the Company's Common Shares at 19 May 2015, and the closing US/£ exchange rate at that date.

 

 

For further information please contact:

 

MyCelx Technologies Corporation

Connie Mixon, CEO

Mark Clark, CFO

Tel: +1 888 306 6843

 

Numis Securities Limited

Corporate Finance

John Prior

Paul Gillam

 

Corporate Broking

James Black

Ben Stoop

Tel: +44 20 7260 1000

 

Bell Pottinger

Nick Lambert

Henry Lerwill

Tel: +44 20 3772 2500

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSLLFEVETILFIE
Date   Source Headline
3rd Jun 20267:00 amRNSAppointment of Non-Executive Director
12th May 20267:00 amRNSNew Gulf of Mexico Lease Award with Super Major
7th May 20267:00 amRNSFinal Results for the Year Ending 31 December 2025
16th Feb 202610:46 amRNSDirector Dealing
20th Jan 20267:00 amRNSTrading Update
22nd Dec 202511:27 amRNSHolding(s) in Company
7th Nov 20252:51 pmRNSHolding(s) in Company
3rd Nov 20257:00 amRNSTrading Update & $3.9m Project Award
1st Oct 20257:00 amRNSHolding(s) in Company
23rd Sep 20255:00 pmRNSResult of Annual Meeting
23rd Sep 20257:00 amRNSAppointment of New Chairman and Succession
17th Sep 20257:00 amRNSHalf Year Results Statement
11th Sep 20257:00 amRNSClosure of Restricted Stock Line
22nd Aug 20257:00 amRNSMailing of Notice of 2025 Annual Meeting
20th Aug 20257:00 amRNSOpening of $500,000 Line of Credit
17th Jul 20257:00 amRNSTrading Update
10th Jun 20257:00 amRNSMailing of 2024 Annual Report
21st May 20253:25 pmRNSDirector Dealing
19th May 202511:33 amRNSHolding(s) in Company
15th May 202511:21 amRNSHolding(s) in Company
12th May 20257:00 amRNSFinal Results for the Year Ending 31 December 2024
6th May 20257:00 amRNSPFAS Contract Award
1st May 20257:00 amRNS-REPA Announces Actions to Combat PFAS Contamination
10th Apr 20257:00 amRNSGrant of Share Options
7th Apr 20257:00 amRNSOperational and Trading Update
30th Jan 20257:00 amRNSChange of Adviser
6th Jan 20257:00 amRNSYear-end Update
29th Oct 20247:00 amRNSProject Award
24th Sep 20247:00 amRNSHalf Year Results Statement
23rd Sep 20247:00 amRNSTrading Update
6th Sep 202411:54 amRNSHolding(s) in Company
5th Sep 20245:17 pmRNSHolding(s) in Company
30th Aug 20247:00 amRNSBroker Option
23rd Aug 202411:05 amRNSDirector Dealings & Total Voting Rights
23rd Aug 20247:00 amRNSProposed Placing and Subscription
19th Jul 202410:36 amRNSPFAS Update
9th Jul 20242:23 pmRNSResult of AGM
9th Jul 20241:39 pmRNSHolding(s) in Company
4th Jun 20247:00 amRNS2023 Annual Report & Notice of 2024 Annual Meeting
21st May 20247:00 amRNSDirector Dealing
16th May 20247:00 amRNSFinal Results for the Year Ending 31 December 2023
24th Apr 20247:00 amRNSBusiness Update
11th Apr 20247:00 amRNSEPA Publishes National Drinking Water Standards
26th Mar 20243:30 pmRNSDirector Dealing
26th Mar 20247:00 amRNSDirector Dealing
22nd Mar 20247:00 amRNSDirector Dealing
21st Mar 20247:00 amRNSDirector Dealing
18th Mar 20247:00 amRNSGrant of Share Options to Chief Financial Officer
4th Mar 20247:00 amRNSSaudi Arabia Business Operation Sale Completion
22nd Feb 20247:02 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.